Breakthrough in hemophilia A treatment: Sobi’s ALTUVOCT receives EU marketing authorization

FHS
June 22, 2024
6:24 am

Sobi® today announced the European Commission has granted Marketing Authorization for ALTUVOCT™ (efanesoctocog alfa), for the treatment and prevention of bleeds and perioperative prophylaxis in hemophilia A. ALTUVOCT is a high-sustained factor VIII replacement therapy for all ages and any disease severity.

Exercise beneficial and safe for older people with multiple chronic conditions or risks

A recent study shows exercise is also beneficial and safe for older people with multiple chronic conditions or risk factors. Exercise can improve physical fitness

March 22, 2024

FDA rejects Melinta, Venatorx’s UTI antibiotic over CMC issues

The FDA handed a CRL to Melinta Therapeutics and Venatorx Pharmaceuticals for their urinary tract infection antibiotic, with the agency calling for more information on

February 24, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.

Breakthrough in hemophilia A treatment: Sobi’s ALTUVOCT receives EU marketing authorization

Exercise beneficial and safe for older people with multiple chronic conditions or risks

FDA rejects Melinta, Venatorx’s UTI antibiotic over CMC issues

Study finds link between DHX9 gene mutations and neurodevelopmental disorders

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

Subscribe